Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Price Target at $14.25

by · The Cerbat Gem

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $14.25.

Several research firms recently commented on CRVS. Wall Street Zen raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Mizuho set a $13.00 price objective on Corvus Pharmaceuticals in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Thursday, December 11th. Finally, Barclays initiated coverage on shares of Corvus Pharmaceuticals in a report on Monday, October 13th. They set an “overweight” rating and a $16.00 price target on the stock.

Get Our Latest Report on Corvus Pharmaceuticals

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Quarry LP purchased a new position in shares of Corvus Pharmaceuticals in the third quarter worth about $27,000. Russell Investments Group Ltd. acquired a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at about $49,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $49,000. BNP Paribas Financial Markets boosted its holdings in shares of Corvus Pharmaceuticals by 125.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,516 shares of the company’s stock worth $92,000 after purchasing an additional 6,975 shares during the last quarter. Finally, Sender Co & Partners Inc. purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $52,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Stock Down 3.2%

CRVS stock opened at $7.45 on Friday. The stock has a market capitalization of $556.37 million, a PE ratio of -14.06 and a beta of 0.64. Corvus Pharmaceuticals has a 52 week low of $2.54 and a 52 week high of $9.60. The firm has a 50 day moving average of $8.11 and a 200 day moving average of $6.28.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, equities research analysts expect that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.

See Also